Purpose: The primary purpose of this study was to clinically evaluate circulating tumor DNA
(ctDNA) with a nine gene, 96 mutation panel among subjects at increased risk for cancer …

Aim: Detection of circulating tumor DNA (ctDNA) holds promise as an adjunct to traditional
cancer screening methods. To determine the sensitivity and specificity of ctDNA …

The important conclusion that ctDNA is a mediocre proxy for liquid biopsies of tumor tissues
for early detection was reached after new data were published recently in Nature Genetics …

Purpose This study aimed to investigate factors, which influence the content of circulating
tumor DNA (ctDNA). Methods 398 serial plasma samples were collected within 1–7 …

Various recent studies have focused on analyzing tumor genetic material released into the
blood stream, known as circulating tumor DNA (ctDNA). Herein, we describe current …

Human blood contains cell-free DNA (cfDNA), with circulating tumor-derived DNAs (ctDNAs)
widely used in cancer diagnosis and treatment. However, it is still difficult to efficiently and …

3040 Background: Pembrolizumab was recently FDA approved across solid tumors for TMB
scores≥ 10mut/Mb as assessed by next-generation sequencing (NGS) of tissue (tTMB). A …

Background Several circulating tumor DNA (ctDNA) profiling assays are commercially
available, and physicians must be empowered to identify assays with the high level of …

3559 Background: Recently, conflicting evidence has emerged showing the association of
ctDNA level and cancer progression. The aim of our study was the development of a method …

The detection of cancer at an early stage while it is curable by surgical resection is widely
believed to be one of the most effective strategies for reducing cancer mortality. Hence, the …